Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.80 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9151071 | 1.00 | CYP1A2 (0.80) | CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL9152244 | 1.00 | CYP1A2 (0.80) | CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL9150946 | 1.00 | CYP1A2 (0.80) | CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL9149589 | 1.00 | CYP1A2 (0.80) | CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL11851576 | 1.00 | CYP1A2 (0.80) | CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL10448990 | 0.98 | CYP1A2 (0.84) | CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL7364534 | 0.98 | CYP1A2 (0.84) | CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL26495605 | 0.98 | CYP1A2 (0.84) | CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL26495548 | 0.98 | CYP1A2 (0.84) | CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1 | |
| SCHEMBL27033239 | 0.98 | CYP1A2 (0.84) | CYP1A2MAPK1SMN1; SMN2HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-5472946-A | Topical administration of lincomycin, clindamycin, erthromycin and iododeoxyuridine on skin or mucuous membranes | DISCOVERY THERAPEUTICS, INC. | 1995-12-05 | — | — | US | disclosed |
| US-5470848-A | Penetration enhancers for transdermal delivery of systemic agents | DISCOVERY THERAPEUTICS, INC. | 1995-11-28 | — | — | US | disclosed |
| US-5444075-A | Penetration enhancers for transdermal delivery of systemic agents | MINASKANIAN GEVORK (US) | 1995-08-22 | — | — | US | disclosed |
| US-5234959-A | Omega-dialkylaminoalkanoic acids; drug delivery directly to the bloodstream | WHITBY RESEARCH, INC. (US) | 1993-08-10 | — | — | US | disclosed |
| US-5118692-A | Penetration enhances for transdermal delivery of systemic agents | WHITBY RESEARCH, INC. (US) | 1992-06-02 | — | — | US | disclosed |
| US-5118676-A | Administering carboxylic derivatives as enhancer with systemically active agents | WHITBY RESEARCH, INC. (US) | 1992-06-02 | — | — | US | disclosed |
| US-4996199-A | Penetration enhancers for transdermal delivery of systemic agents | WHITBY RESEARCH, INC. (US) | 1991-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | CYP1A2 4878/4885MAPK1 4305/4885SMN1; SMN2 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.